BR112015004471A8 - formulação em comprimido de composto com duas camadas constituído por atorvastatina, irbesartan e carbonato de magnésio - Google Patents

formulação em comprimido de composto com duas camadas constituído por atorvastatina, irbesartan e carbonato de magnésio Download PDF

Info

Publication number
BR112015004471A8
BR112015004471A8 BR112015004471A BR112015004471A BR112015004471A8 BR 112015004471 A8 BR112015004471 A8 BR 112015004471A8 BR 112015004471 A BR112015004471 A BR 112015004471A BR 112015004471 A BR112015004471 A BR 112015004471A BR 112015004471 A8 BR112015004471 A8 BR 112015004471A8
Authority
BR
Brazil
Prior art keywords
irbesartan
atorvastatin
magnesium carbonate
tablet formulation
layer compound
Prior art date
Application number
BR112015004471A
Other languages
English (en)
Other versions
BR112015004471A2 (pt
Inventor
Jung Cho Hyun
Hyun Park Jae
Soo Woo Jong
Young Choi Jun
Ii Kim Yong
Keun Choi Young
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50183917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015004471(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of BR112015004471A2 publication Critical patent/BR112015004471A2/pt
Publication of BR112015004471A8 publication Critical patent/BR112015004471A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo “formulação de tablete de composto com duas camadas constituído por atorvastatina, irbesartan e carbonato de magnésio “ é apresentada uma formação de tablete de composto com duas camadas compreendendo (a) uma primeira camada constituída por irbesartan ou um sal farmaceuticamente aceitável do mesmo; e (b) uma segunda camada compreendendo atorvastatina ou um sal farmaceuticamente aceitável da mesma e carbonato de magnésio (mgco3) em uma proporção em peso de 1:4 a 1:5, e um método para a preparação do mesmo. exibindo excelentes taxas de dissolução e de biodisponibilidade, a formulação de tablete de composto com duas camadas é útil como um produto terapêutico para a hipertensão e a hipercolesteromia.
BR112015004471A 2012-08-31 2013-08-30 formulação em comprimido de composto com duas camadas constituído por atorvastatina, irbesartan e carbonato de magnésio BR112015004471A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120096477A KR20140028971A (ko) 2012-08-31 2012-08-31 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
PCT/KR2013/007838 WO2014035188A1 (en) 2012-08-31 2013-08-30 Bilayered composite tablet formulation comprising atorvastatin, irbesartan and magnesium carbonate

Publications (2)

Publication Number Publication Date
BR112015004471A2 BR112015004471A2 (pt) 2017-07-04
BR112015004471A8 true BR112015004471A8 (pt) 2019-08-27

Family

ID=50183917

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015004471A BR112015004471A8 (pt) 2012-08-31 2013-08-30 formulação em comprimido de composto com duas camadas constituído por atorvastatina, irbesartan e carbonato de magnésio

Country Status (31)

Country Link
US (1) US20150209290A1 (pt)
EP (1) EP2890368A4 (pt)
JP (1) JP6363079B2 (pt)
KR (1) KR20140028971A (pt)
CN (1) CN104602677A (pt)
AR (1) AR092386A1 (pt)
AU (1) AU2013309686B2 (pt)
BR (1) BR112015004471A8 (pt)
CA (1) CA2882735A1 (pt)
CL (1) CL2015000402A1 (pt)
CR (1) CR20150115A (pt)
DO (1) DOP2015000040A (pt)
EA (1) EA030306B1 (pt)
EC (1) ECSP15010600A (pt)
GT (1) GT201500043A (pt)
IL (1) IL237424A0 (pt)
IN (1) IN2015DN01463A (pt)
MA (1) MA37951B2 (pt)
MX (1) MX354800B (pt)
MY (1) MY175897A (pt)
NI (1) NI201500027A (pt)
NZ (1) NZ706472A (pt)
PE (1) PE20150935A1 (pt)
PH (1) PH12015500394A1 (pt)
RU (1) RU2015111546A (pt)
SG (1) SG11201500584YA (pt)
TW (1) TWI651101B (pt)
UA (1) UA115995C2 (pt)
UY (1) UY35001A (pt)
WO (1) WO2014035188A1 (pt)
ZA (1) ZA201502156B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6981088B2 (ja) * 2017-01-27 2021-12-15 ニプロ株式会社 経口固形製剤
CR20190577A (es) * 2017-07-17 2020-01-29 Lilly Co Eli Composiciones farmacéuticas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
PE20030324A1 (es) 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
AR060354A1 (es) * 2006-04-06 2008-06-11 Schering Corp Terapias de combinacion antagonistas receptor trombina (tra)
KR20090114325A (ko) * 2008-04-29 2009-11-03 한올제약주식회사 약제학적 제제
JP5534004B2 (ja) * 2010-03-29 2014-06-25 アステラス製薬株式会社 口腔内崩壊錠
KR101248804B1 (ko) * 2010-05-14 2013-03-29 한미사이언스 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제

Also Published As

Publication number Publication date
ECSP15010600A (es) 2015-12-31
AU2013309686B2 (en) 2017-09-07
AR092386A1 (es) 2015-04-22
CA2882735A1 (en) 2014-03-06
CR20150115A (es) 2015-04-16
MA37951A1 (fr) 2018-06-29
JP6363079B2 (ja) 2018-07-25
AU2013309686A1 (en) 2015-02-26
WO2014035188A1 (en) 2014-03-06
PH12015500394A1 (en) 2015-04-27
EA201590469A1 (ru) 2015-06-30
IL237424A0 (en) 2015-04-30
UY35001A (es) 2014-03-31
KR20140028971A (ko) 2014-03-10
JP2015530384A (ja) 2015-10-15
GT201500043A (es) 2017-08-24
EA030306B1 (ru) 2018-07-31
PE20150935A1 (es) 2015-06-20
BR112015004471A2 (pt) 2017-07-04
NZ706472A (en) 2018-02-23
US20150209290A1 (en) 2015-07-30
MY175897A (en) 2020-07-14
EP2890368A1 (en) 2015-07-08
TW201414507A (zh) 2014-04-16
UA115995C2 (uk) 2018-01-25
ZA201502156B (en) 2016-07-27
MX2015002526A (es) 2015-06-23
CN104602677A (zh) 2015-05-06
IN2015DN01463A (pt) 2015-07-03
MX354800B (es) 2018-03-22
DOP2015000040A (es) 2015-04-15
TWI651101B (zh) 2019-02-21
MA37951B2 (fr) 2019-12-31
RU2015111546A (ru) 2016-10-20
NI201500027A (es) 2017-01-04
EP2890368A4 (en) 2016-03-02
SG11201500584YA (en) 2015-02-27
CL2015000402A1 (es) 2015-06-05

Similar Documents

Publication Publication Date Title
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
EA202091303A2 (ru) Композиция ингибитора jak для местного применения
PE20140163A1 (es) Composiciones terapeuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
EA201071204A1 (ru) Применение дронедарона для приготовления лекарственного средства для применения в предотвращении госпитализации в кардиологическое отделение или смертности
AR085173A1 (es) Terapia de combinacion para el tratamiento de enfermedades oncologicas y fibroticas
UA107967C2 (en) Pharmaceutical composition in the form of bilayer tablets which contain inhibitor of hmg-coa reductase inhibitor and irbesartan
ECSP13012847A (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación.
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
PH12015501386A1 (en) Tricyclic compounds
MX2016007682A (es) Composicion farmaceutica que comprende ivabradina amorfa.
PH12015500395A1 (en) Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
AR084882A1 (es) Compuesto de 1-azabiciclo[2.2.2]octano y usos para el tratamiento de esquizofrenia
BR112015004471A8 (pt) formulação em comprimido de composto com duas camadas constituído por atorvastatina, irbesartan e carbonato de magnésio
HRP20160387T1 (hr) Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor
CL2008003584A1 (es) Uso de la 10-[(3r)-1-azabiciclo]oct-3-ilmetil]-10-h-fenotiazina, o una de sus sales farmaceuticamente aceptables para la preparación de un medicamento util para prevenir o tratar la bronconeumopatia obstructiva.
TH155663A (pt)
WO2011161123A3 (en) Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
TR201005911A2 (tr) Geliştirilmiş dissolüsyon profiline sahip bir ilaç formülasyonu.
UA105513C2 (uk) Лікарська форма уповільненого вивільнення глюкозаміну

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2685 DE 21-06-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.